ArticleAmerican journal of translational research2021
Application of antagonist regimen in patients with failed pregnancy assisted by previous long-term regimen during early follicular phase.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Recommendations for the management of GnRH-ant for ovarian stimulation in the assistant reproductive process: Benefits and harms for different ovarian response population.Clinical and public health guidelines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical application of gonadotropin-releasing hormone antagonist (GnRH-ant) in patients with failed pregnancy assisted by the previous long-term regimen during early follicular phase (EFP).
methodsA total of 122 patients with good ovarian function and two previous failed EFP long-term assisted pregnancy were selected from the reproductive center of our hospital for study. All patients were assisted by in vitro fertilization-embryo transfer (IVF-ET) twice. According to the random number table method, the participants were divided into group A (n=61) for subcutaneous injection of gonadotropin-releasing hormone agonist (GnRH-a) and group B (n=61) for GnRH-ant, and the clinical efficacy of the two groups were observed.
resultsGroup B presented reduced dosage and duration of Gn, increased number and probability of eggs retrieved, and increased number of 2PN, cleavage and transplantable embryos than group A (all P<0.05). Serum estradiol (E2) and luteinizing hormone (LH) levels elevated and T level decreased in group B as compared to group A (all P<0.05). There was no significant difference in follicle-stimulating hormone (FSH) indexes between the two groups (P>0.05). Endometrial thickness and mean ovarian volume (MOV, the mean volume of bilateral ovaries) were not significantly different between group A and group B before treatment (both P>0.05), while were lower in group B than in group A after treatment (both P<0.05). Group B had higher high-quality egg rate (%), fertilization rate (should have numbers here %), cleavage rate (%), high-quality embryo rate (should have numbers here %) and cumulative pregnancy rate (%) than group A (all P<0.05). The incidences of moderate OHSS, early abortion and hydrosalpinx were lower in group B than in group A (all P<0.05), while there was no evident difference between the two groups in the occurrence of severe OHSS and ectopic pregnancy (both P>0.05).
conclusionGnRH-ant can improve the clinical high-quality embryo rate in patients with the previous failed EFP long-term assisted pregnancy, and reduce the occurrence of OHSS events. Compared with GnRH-a, GnRH-ant is more suitable for clinical application of controlled ovarian hyperstimulation.
Indexed as
Identifiers
34377329PMC8340165W3190801457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.